GlassScriptPhysician profile
Clenton Coleman
NPI 1730379025
$1,308.62
in general payments reported to CMS, 2019-2025
26 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $110 · 2021: $207 · 2022: $95.92 · 2023: $18.68 · 2024: $320 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381 · Education: $64.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.19 |
| Education | $64.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $141.47 | 2019-2022 | |
| Mozarc Medical US LLC | $119.05 | 2024 | Argyle |
| Novo Nordisk INC | $117.78 | 2021-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $104.91 | 2019 | |
| Genentech USA, INC. | $94.00 | 2019 | |
| Amgen INC. | $88.48 | 2020-2022 | |
| Akebia Therapeutics INC | $80.83 | 2021-2024 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $56.60 | 2019-2021 | |
| Vifor Pharma, INC. | $55.52 | 2019-2021 | |
| Horizon Therapeutics Plc | $55.22 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $51.50 | 2019-2025 | Velphoro |
| Amarin Pharma, INC. | $42.59 | 2021 | |
| Shire North American Group INC | $41.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.03 | 2022-2024 | |
| Ardelyx, INC. | $32.39 | 2024 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $27.18 | 2024 | Renal - Pd |
| Glaxosmithkline, LLC. | $26.44 | 2021-2024 | Trelegy Ellipta |
| Recor Medical INC | $25.49 | 2024 | Paradise Renal Denervation System |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.00 | 2025 | Ultomiris |
| Abbvie INC. | $14.81 | 2021 | |
| Lilly USA, LLC | $13.90 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.20 | 2021 | |
| Travere Therapeutics, INC. | $7.23 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clenton Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.